Ironwood Pharmaceuticals, Inc.

NasdaqGS:IRWD Stock Report

Market Cap: US$311.9m

Ironwood Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:IRWD Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
11 Aug 25SellUS$1,105Tammi GaskinsIndividual1,316US$0.84
11 Aug 25SellUS$2,391Ronald SilverIndividual2,846US$0.84
11 Aug 25SellUS$6,513John MinardoIndividual7,754US$0.84
11 Aug 25SellUS$1,063Gregory MartiniIndividual1,265US$0.84
16 May 25SellUS$1,487Tammi GaskinsIndividual2,563US$0.58
16 May 25SellUS$7,745Thomas McCourtIndividual13,353US$0.58
10 Feb 25SellUS$68,531John MinardoIndividual38,938US$1.76
10 Feb 25SellUS$21,212Gregory MartiniIndividual12,052US$1.76
10 Feb 25SellUS$21,204Ronald SilverIndividual12,048US$1.76
10 Feb 25SellUS$72,633Michael ShetzlineIndividual41,269US$1.76
10 Feb 25SellUS$244,753Thomas McCourtIndividual139,064US$1.76
18 Nov 24SellUS$44,884Sravan EmanyIndividual11,001US$4.08
18 Nov 24SellUS$21,869Andrew DavisIndividual5,360US$4.08

Insider Trading Volume

Insider Buying: IRWD insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of IRWD?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders3,880,3432.39%
General Public12,159,8237.49%
Hedge Funds40,475,60424.9%
Institutions105,918,36065.2%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 79.85% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.97%
The Vanguard Group, Inc.
16,202,129US$31.1m3.22%no data
9.94%
Armistice Capital LLC
16,150,000US$31.0m17.9%0.81%
9.8%
Sarissa Capital Management LP
15,919,435US$30.6m0%16.17%
7.4%
BlackRock, Inc.
12,022,998US$23.1m1.21%no data
5.18%
Renaissance Technologies LLC
8,406,169US$16.1m-15.4%0.02%
4.03%
Acadian Asset Management LLC
6,549,687US$12.6m148%0.02%
3.69%
AQR Capital Management, LLC
5,991,961US$11.5m139%0.01%
3.37%
Kynam Capital Management, LP
5,466,825US$10.5m-6.12%0.77%
2.46%
Marshall Wace LLP
3,993,557US$7.7m616%0.01%
2.26%
Charles Schwab Investment Management, Inc.
3,664,276US$7.0m0%no data
2.15%
Geode Capital Management, LLC
3,499,332US$6.7m2.38%no data
2.08%
Two Sigma Advisers, LP
3,384,100US$6.5m79.6%0.01%
2.06%
Bank of America Corporation
3,352,372US$6.4m136%no data
2.06%
Qube Research & Technologies Ltd
3,351,002US$6.4m1.33%0.01%
1.91%
State Street Global Advisors, Inc.
3,107,719US$6.0m-11.2%no data
1.69%
Two Sigma Investments, LP
2,750,573US$5.3m124%0.01%
1.69%
LSV Asset Management
2,750,200US$5.3m-31.2%0.01%
1.36%
Connor, Clark & Lunn Investment Management Ltd.
2,206,948US$4.2m48.3%0.01%
1.34%
Federated Hermes, Inc.
2,177,038US$4.2m66.8%0.01%
1.03%
D. E. Shaw & Co., L.P.
1,669,639US$3.2m1,420%no data
1.02%
Jane Street Group, LLC
1,656,759US$3.2m-52.8%0.01%
0.94%
Deutsche Asset & Wealth Management
1,523,337US$2.9m-1.98%no data
0.91%
Jacobs Levy Equity Management Inc
1,475,046US$2.8m-6.66%0.01%
0.8%
Northern Trust Global Investments
1,305,265US$2.5m-7.2%no data
0.7%
Los Angeles Capital Management LLC
1,130,052US$2.2m-6.7%0.01%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/03 03:07
End of Day Share Price 2025/11/03 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ironwood Pharmaceuticals, Inc. is covered by 29 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamBarclays
Patrick TrucchioBerenberg
David MarisBMO Capital Markets Equity Research